Request Appointment
160 East 53rd StreetNew York, NY 10022
Overview of Dr. Diamond
Dr. Eli Diamond is a neurologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Albert Einstein College of Medicine and has been in practice 18 years. He is one of 67 doctors at Memorial Sloan Kettering Cancer Center who specialize in Neurology. He has more than 100 publications and over 500 citings.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 2008 - 2011
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 2007 - 2008
Albert Einstein College of MedicineClass of 2007
Certifications & Licensure
FL State Medical License 2022 - Present
CT State Medical License 2025 - 2027
NJ State Medical License 2022 - 2027
NY State Medical License 2011 - 2026
NC State Medical License 2020 - 2022
MA State Medical License 2009 - 2012
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017
- CMS Meaningful Use Stage 1 Certification MyMSK, Memorial Sloan Kettering, 2016-2017
Publications & Presentations
PubMed
- Subfoveal Choroidal Thickness in Patients with Histiocytosis and Multimodal Imaging Features of Choroidal Infiltrates.Jasmine H Francis, Anne S Reiner, Julia Canestraro, David H Abramson, Eli L Diamond
Ophthalmology. Retina. 2025-06-01 - 6 citationsApproach to the Patient: From Endocrinopathy to the Diagnosis of a Histiocytic Disorder.Polyzois Makras, Dana Erickson, Caroline J Davidge-Pitts, Eli L Diamond, Carl E Allen
The Journal of Clinical Endocrinology and Metabolism. 2025-05-19 - 7 citationsTreatment holidays in patients with Erdheim-Chester disease receiving vemurafenib: a prospective pilot study.Francesco Pegoraro, Francesco Catamerò, Federica Allegretta, Giulia Palazzini, Francesco Peyronel
Blood Advances. 2025-05-13
Press Mentions
FDA Approves First Treatment for Patients with All Forms of HistiocytosisJanuary 30th, 2023
High Response Rate in Histiocytic Disease with MEK InhibitionJanuary 3rd, 2018
NCCN Foundation Awards Grants to Five Young InvestigatorsApril 1st, 2016
Grant Support
- Molecular Pathogenesis and Therapy of Systemic Histiocytic NeoplasmsSLOAN-KETTERING INST CAN RESEARCH2021–2026
- Defining Clinical Research Priorities and Strengthening Diversity and Patient-Stakeholder Engagement in Histiocytic DisordersST. JUDE CHILDREN'S RESEARCH HOSPITAL2024
